AstaZeneca in patent warning as net profit falls

(AP)—Anglo-Swedish pharmaceutical company AstraZeneca PLC warned over expiring patents on its medicines as the company announced a 37 percent fall in full-year net profit on Thursday.

AstraZeneca said that its net profit fell to $6.3 billion in the year ended Dec. 31, compared with nearly $10 billion in 2011. The company blamed the loss of exclusivity on several big-name drugs for a drop in revenue to $28 billion from $33.6 billion a year earlier, and warned it expects the trend to continue hitting sales in 2013.

Chief executive Pascal Soriot said Thursday the company's 2012 performance "reflects a period of significant patent expiry and tough market conditions."

He said AstraZeneca's new leadership team would focus on the company's brands and developmental pipeline.

Patents are crucial assets for pharmaceutical companies, which use them to insulate their expensive, brand-name drugs from competition from cheap, generic versions. Expiring patents on several of AstraZeneca's top drugs translates to weaker revenue as the company cuts prices or surrenders market share.

AtraZeneca reported that U.S. revenue fell 21 percent, largely due to competition from of its anti-depression medication, Seroquel IR, whose patent expired last year.

The company said that nearly two thirds of its 19 percent loss in revenue in Western Europe was the result of generic competition for Seroquel IR, as well as drug Nexium, Atacand, and skin medication Merrem.

In Canada, to cholesterol-control drug Crestor dragged revenue down 31 percent.

The company said it expects challenging market conditions to persist in 2013, with the first quarter of the year expected to be "particularly challenging" since and —in Canada—haven't yet reached a full year since generics entered the market.

At Hargreaves Landsdowne, equity analyst Keith Bowman warned that, unlike other companies in the medical field, AstraZeneca "does not enjoy the cushion of alternative revenue streams such as consumer health care" and noted a "general lack of optimism" surrounding its developmental pipeline.

But Panmure analyst Savvas Neophytou said the results were "not as bad as they could have been," noting that fourth-quarter results were more resilient than expected.

AstraZeneca's fourth-quarter net profit edged higher to 1.52 billion pounds from 1.49 billion pounds in the same period a year earlier, while revenue slipped to 7.3 billion pounds from 8.7 billion pounds.

Stocks in fell 4.8 percent to 30 pounds a share in early morning trading on the London Stock Exchange.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Eli Lilly 2013 profit forecast tops expectations

Jan 04, 2013

(AP)—Eli Lilly and Co. said Friday its 2013 earnings will grow more than Wall Street expects, even though the drugmaker will lose U.S. patent protection for two more key products this year.

Taiwan's HTC expects 30 percent sales plunge in 1Q

Feb 06, 2012

Taiwan's leading smartphone maker HTC forecast Monday that its revenue in the three months to March may plunge 30 percent from a year ago, as competitors Apple and Samsung take their grip on the market.

Texas Instruments lowers 4Q outlook

Dec 09, 2011

(AP) -- Semiconductor maker Texas Instruments Inc. lowered its outlook for its fourth-quarter revenue and profit on Thursday, saying demand had weakened for a variety of products that use its chips.

Amgen 4Q profit drops 16 pct. on higher spending

Jan 23, 2013

Drugmaker Amgen Inc. on Wednesday posted a 16 percent drop in fourth-quarter profit, as higher costs for production, marketing, research and other items offset higher sales for many of its biologic medicines. The results ...

Recommended for you

Were clinical trial practices in East Germany questionable?

9 hours ago

Clinical trials carried out in the former East Germany in the second half of the 20th century were not always with the full knowledge or understanding of participants with some questionable practices taking place, according ...

Schumacher's doctor sees progress after injury

Oct 23, 2014

A French physician who treated Michael Schumacher for nearly six months after the Formula One champion struck his head in a ski accident says he is no longer in a coma and predicted a possible recovery within three years.

User comments